Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| InMed Pharmaceuticals Inc.INM · Entity 8139 | Director | January 24, 2022 | January 24, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
InMed Pharmaceuticals Inc.
Report date January 24, 2022 · Filed January 24, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee Stock Option (Expiration)SEC Table II · derivative / convertible security · Conversion / exercise price $3.42 · Expires 2022-01-24 | Direct | 16,122 |
Reported balance
After 2022-01-24 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-01-24 · Other · Disposed 24,242 · Balance 16,122 F1: Converted from the Canadian dollar exercise price of C$4.29 using an exchange rate of C$1.2554 = $US1.00 |
Filing footnotes · ownership attribution and instrument terms
F1: Converted from the Canadian dollar exercise price of C$4.29 using an exchange rate of C$1.2554 = $US1.00
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 24, 2022 Filed Jan 24, 2022 16:19 UTC | InMed Pharmaceuticals Inc. INM · Entity 8139 | OtherEmployee Stock Option (Expiration) · Derivative | 24,242 | $0.00 Strike: $3.42 | $0.00 |
DisclosureSEC source: 0001213900-22-003334 · ownership.xml · derivative · entry 1 Garner William J · CIK 0001407235 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,122 Underlying: Common shares · 24,242 shares Expires 2022-01-24 F1 · derivative.exercise_price: Converted from the Canadian dollar exercise price of C$4.29 using an exchange rate of C$1.2554 = $US1.00 Read SEC document |
| December 29, 2021 Filed Dec 30, 2021 18:01 UTC | InMed Pharmaceuticals Inc. INM · Entity 8139 | GrantEmployee Stock Option (Right to Buy) · Derivative | 7,000 | $0.00 Strike: $1.32 | $0.00 |
DisclosureSEC source: 0001213900-21-068183 · ownership.xml · derivative · entry 1 Garner William J · CIK 0001407235 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,364 Underlying: Common shares · 7,000 shares Expires 2026-12-28 F1 · derivative.exercise_date: The options were granted on 12/16/2020 and will vest 100% on the one year anniversary of the grant date (Dec 16, 2021) or immediately prior to the next AGM, whichever is sooner. Read SEC document |
| December 16, 2020 Filed Dec 18, 2020 06:17 UTC | InMed Pharmaceuticals Inc. INM · Entity 8139 | GrantEmployee Stock Option (Right to Buy) · Derivative | 7,000 | $0.00 Strike: $3.02 | $0.00 |
DisclosureSEC source: 0001213900-20-043362 · ownership.xml · derivative · entry 1 Garner William J · CIK 0001407235 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,000 Underlying: Common shares · 7,000 shares Expires 2025-12-15 F1 · derivative.exercise_price: The Canadian exercise price of C$3.85 was converted into U.S. dollars using an exchange rate of C$1.2753 = US$1.00. F2 · derivative.exercise_date: The options were granted on 12/16/2020 and will vest 100% on the one year anniversary of the grant date (Dec 16, 2021) or immediately prior to the next AGM, whichever is sooner. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.